质子帮浦抑制剂市场－全球产业规模、份额、趋势、机会和预测，按药物类型、疾病分类、应用、地区和竞争格局划分，2020-2030年预测

2024年全球质子帮浦抑制剂市场规模为31.5亿美元，预计到2030年将以4.87%的复合年增长率成长至41.9亿美元。质子帮浦抑制剂是一类药物，旨在透过不可逆地阻断胃壁细胞的氢钾ATP酶系统来减少胃酸分泌。全球质子帮浦抑制剂市场需求成长的主要驱动因素是胃食道逆流、消化性溃疡和其他酸相关胃肠道疾病在全球范围内的日益普遍，以及老年人口的不断增长，老年人更容易患上这些疾病。

主要市场驱动因素

全球质子帮浦抑制剂（PPI）市场正经历显着成长，主要驱动因素是胃食道逆流和消化性溃疡的盛行率不断上升，以及老年人口不断增长导致胃肠道疾病易感性增加。胃食道逆流和消化性溃疡等疾病的广泛发生构成了对PPI的基本需求，因为PPI能够有效控制酸相关症状并促进癒合。

主要市场挑战

质子帮浦抑制剂的长期安全性对其市场扩张构成了显着挑战。越来越多的临床证据和监管机构对长期使用可能产生的不良反应的日益严格的审查，正日益影响医疗服务提供者的处方模式。

主要市场趋势

先进的PPI製剂和递送方式的创新是製药业为提升治疗效果、提高患者依从性并减轻潜在的长期副作用而不断努力的推动力。这一趋势包括开发新型药物递送系统和製剂，以期实现更快的起效或更长的疗效。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球质子帮浦抑制剂市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类型（泮托拉唑、奥美拉唑、兰索拉唑、埃索美拉唑、雷贝拉唑、右兰索拉唑、其他）
  • 依疾病分类（溃疡、胃食道逆流、其他）
  • 按应用（医院、诊所、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美质子帮浦抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲质子帮浦抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区质子帮浦抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲质子帮浦抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲质子帮浦抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球质子帮浦抑制剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Bayer AG
• AstraZeneca PLC
• Pfizer, Inc.
• Eli Lilly and Co Ltd
• Teva Pharmaceutical Industries Ltd
• Cadila Pharmaceuticals Ltd
• Johnson & Johnson
• Takeda Pharmaceutical Co Ltd
• Eisai Co Ltd

第十六章：策略建议

第17章调查会社について・免责事项

The Global Proton Pump Inhibitors Market, valued at USD 3.15 Billion in 2024, is projected to experience a CAGR of 4.87% to reach USD 4.19 Billion by 2030. Proton Pump Inhibitors are a class of pharmaceutical compounds designed to reduce gastric acid secretion by irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme system of gastric parietal cells. The global market for these agents is driven by the increasing worldwide prevalence of gastroesophageal reflux disease, peptic ulcer disease, and other acid-related gastrointestinal disorders, coupled with an expanding geriatric population more susceptible to such conditions.

Key Market Drivers

The global Proton Pump Inhibitors market experiences substantial growth, primarily propelled by the escalating prevalence of gastroesophageal reflux disease and peptic ulcers, alongside the expanding geriatric population's increased susceptibility to gastrointestinal disorders. The widespread occurrence of conditions such as GERD and peptic ulcers forms the foundational demand for PPIs, given their efficacy in managing acid-related symptoms and promoting healing. According to Frontiers, in Global, regional, and national burden of gastroesophageal reflux disease (1990-2021): age-period-cohort analysis and Bayesian projections, published in 2023, global GERD prevalence reached 825.6 million cases in 2021, underscoring the significant patient pool requiring effective acid suppression therapies.

Key Market Challenges

The long-term safety profile of Proton Pump Inhibitors presents a notable challenge to market expansion. Growing clinical evidence and heightened regulatory scrutiny regarding potential adverse effects linked to prolonged use are increasingly influencing prescribing patterns among healthcare providers. This necessitates more cautious consideration during patient consultations and can lead to reduced initiation of long-term PPI therapy. Consequently, patient adherence may also be impacted, as individuals become more aware of reported risks, potentially leading to earlier discontinuation of treatment. These dynamics directly impede the sustained growth of the Global Proton Pump Inhibitors Market by tempering the volume of new prescriptions and the duration of existing ones.

Key Market Trends

Innovation in advanced PPI formulations and delivery represents a crucial trend, driven by the pharmaceutical industry's continuous efforts to enhance therapeutic profiles, improve patient adherence, and mitigate potential long-term side effects. This focus includes developing novel drug delivery systems and formulations that offer faster onset of action or prolonged efficacy. For example, Takeda Pharmaceutical Company Limited, in its first-quarter fiscal year 2025 results announced in July 2025, reaffirmed its commitment to discovering and delivering life-transforming treatments in its core therapeutic areas, explicitly including gastrointestinal and inflammation, highlighting ongoing innovation in this critical space.

Key Market Players

• Bayer AG
• AstraZeneca PLC
• Pfizer, Inc.
• Eli Lilly and Co Ltd
• Teva Pharmaceutical Industries Ltd
• Cadila Pharmaceuticals Ltd
• Johnson & Johnson
• Takeda Pharmaceutical Co Ltd
• Eisai Co Ltd

Report Scope:

In this report, the Global Proton Pump Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Proton Pump Inhibitors Market, By Drug Type:

• Pantoprazole
• Omeprazole
• Lansoprazole Esomeprazole Rabeprazole
• Dexlansoprazole Others

Proton Pump Inhibitors Market, By Disease Allocation:

• Ulcers
• Gastroesophageal Reflux Disease
• Others

Proton Pump Inhibitors Market, By Application:

• Hospitals
• Clinic
• Others

Proton Pump Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Proton Pump Inhibitors Market.

Available Customizations:

Global Proton Pump Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Proton Pump Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Pantoprazole, Omeprazole, Lansoprazole Esomeprazole Rabeprazole, Dexlansoprazole, Others)
  • 5.2.2. By Disease Allocation (Ulcers, Gastroesophageal Reflux Disease, Others)
  • 5.2.3. By Application (Hospitals, Clinic, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Proton Pump Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Disease Allocation
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Proton Pump Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Disease Allocation
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Proton Pump Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Disease Allocation
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Proton Pump Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Disease Allocation
      • 6.3.3.2.3. By Application

7. Europe Proton Pump Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Disease Allocation
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Proton Pump Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Disease Allocation
      • 7.3.1.2.3. By Application
  • 7.3.2. France Proton Pump Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Disease Allocation
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Proton Pump Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Disease Allocation
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Proton Pump Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Disease Allocation
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Proton Pump Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Disease Allocation
      • 7.3.5.2.3. By Application

8. Asia Pacific Proton Pump Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Disease Allocation
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Proton Pump Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Disease Allocation
      • 8.3.1.2.3. By Application
  • 8.3.2. India Proton Pump Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Disease Allocation
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Proton Pump Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Disease Allocation
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Proton Pump Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Disease Allocation
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Proton Pump Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Disease Allocation
      • 8.3.5.2.3. By Application

9. Middle East & Africa Proton Pump Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Disease Allocation
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Proton Pump Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Disease Allocation
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Proton Pump Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Disease Allocation
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Proton Pump Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Disease Allocation
      • 9.3.3.2.3. By Application

10. South America Proton Pump Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Disease Allocation
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Proton Pump Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Disease Allocation
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Proton Pump Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Disease Allocation
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Proton Pump Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Disease Allocation
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Proton Pump Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca PLC
• 15.3. Pfizer, Inc.
• 15.4. Eli Lilly and Co Ltd
• 15.5. Teva Pharmaceutical Industries Ltd
• 15.6. Cadila Pharmaceuticals Ltd
• 15.7. Johnson & Johnson
• 15.8. Takeda Pharmaceutical Co Ltd
• 15.9. Eisai Co Ltd

16. Strategic Recommendations

17. About Us & Disclaimer